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A B S T R A C T
Depression can occur before the onset of motor symptoms in Parkinson's disease (PD) patients. The pathophy-
siology of depression in PD involves various brain regions and relevant functional circuits. This study in-
vestigated whether there exist distinctive patterns of presynaptic monoamine transporter densities in the basal
ganglia depending on the degree of depression in patients with PD. A total of 123 early and drug-naïve PD
patients were enrolled. Their affective status was evaluated by the Montgomery–Asberg Depression Rating Scale
(MADRS), and subjects were subgrouped into one of the following three groups according to their MADRS
scores: no depression, mild depression, and moderate-to-severe depression. All patients underwent positron
emission tomography (PET) using 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nor-
tropane. The PET images were normalized, and differences in the regional standardized uptake value ratios
(SUVRs) for each side of the caudate, putamen, globus pallidus, thalamus, and ventral striatum were analyzed
and compared between the three groups. A trend analysis was performed across the groups to discern any
associations between SUVR values of the basal ganglia and depression severity. The SUVR values of the caudate,
anterior caudate nuclei, and ventral striatum declined as MADRS increased. The SUVR values of the striatum
showed an inverse dose-dependent trend of antero- and ventroposterior gradient across the groups. This result
indirectly revealed the involvement of the associative and limbic circuitry of the brain that are modulated by
monoamines in early PD with depression. This might suggest an in vivo causal relationship between the ventral
striatum, caudate and depression.
1. Introduction
Mood disturbances, such as depression, are known to occur even
before the onset of motor symptoms in patients with Parkinson's disease
(PD) (Pont-Sunyer et al., 2015). The prevalence of depression in PD is
estimated to be 30–35%; the mild depressive mood often persists during
disease progression and is a risk factor for moderate to severe depres-
sion (Aarsland et al., 2011).
Depression involves different sets of regional brain circuitry, such as
the limbic and associative loops, and information processing through
these circuits is mediated by distinctive monoamines, such as dopa-
mine, serotonin, and noradrenaline, relevant to the particular brain
areas (Aarsland et al., 2011; Stahl, 2013; Tremblay et al., 2015). When
these connections are disrupted, depression occurs. It has been known
that PD pathology encroaches upon these circuits, evoking mood dis-
orders (Aarsland et al., 2011; Frisina et al., 2009).
18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl)
nortropane (18F-FP-CIT) and positron emission tomography (PET) can
assess the functional integrity of the presynaptic nigrostriatal system. It
has now become an important, albeit not essential, tool in diagnosing
idiopathic PD (Kägi et al., 2010; Postuma et al., 2015). Not only does it
reflect PD severity, it also implicates the interactions of different
monoaminergic systems, such as the dopaminergic, noradrenergic, and
serotonergic systems (Hesse et al., 2009; Remy et al., 2005).
In PD, the posterior and dorsal striatum (sensorimotor territory) is
more affected than the anterior and ventral parts of the striatum (as-
sociative and limbic territories) (Tremblay et al., 2015). Depending on
the distinctive brain circuits, a different threshold of dopaminergic
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availability exists to elicit specific symptoms relevant to particular
areas of the basal ganglia (Tremblay et al., 2015). The hypothesis tested
in this study is that distinctive patterns of presynaptic monoamine
transporter densities in the basal ganglia may exist depending on the
degree of depression in patients with PD. We investigated which areas
of the brain are related to depression in early PD patients and how the
affected regions correlate to the severity of depression.
2. Methods
2.1. Patients
The study protocol was approved by the Institutional Review Board
at Seoul St. Mary's Hospital, and all subjects provided written informed
consent to participate. All experiments were performed in accordance
with relevant guidelines and regulations.
One hundred and twenty-three, early and drug-naïve PD patients
were evaluated between May 2015 and March 2018. Subjects were
diagnosed as having PD according to the criteria of UK PD Society Brain
Bank (Gibb and Lees, 1988). The clinical diagnosis was supported by
18F-FP-CIT PET imaging, which revealed that all patients had decreased
dopamine transporter uptake in the striatum, mainly in the posterior
putamen on visual analysis (Postuma et al., 2015). All enrolled patients
were PD naïve and had not taken any dopaminergic agents or anti-
depressants.
Clinical information was obtained, including age, sex, disease
duration, body mass index, education status, history of hypertension
and diabetes mellitus, and smoking status. Parkinsonian motor symp-
toms were measured using the Unified Parkinson's Disease Rating Scale
(UPDRS) part III and the modified Hoehn and Yahr (H&Y) stage scores.
The UPDRS score was divided into two sub scores: tremor score and
akinetic-rigid score (Schiess et al., 2000). The presence of rest tremor
was defined by≥1 in the UPDRS item 20. General cognitive status was
examined by the Mini-Mental State Examination (MMSE), and com-
prehensive neuropsychiatric tests (Ahn et al., 2010). Each participant's
affective status was screened by the Montgomery–Asberg Depression
Rating Scale (MADRS) (Ahn et al., 2005; Schrag et al., 2007). The
MADRS scores ranged from zero to sixty, and each patient was stratified
into one of the following three groups according to the level of clinical
suspicion based on the MADRS score: Group 1, 0–6, no depression;
Group 2, 7–19, mild depression; and Group 3, scores of≥20, moderate-
to-severe depression (the moderate and severe depression severity
subjects were grouped together due to the small sample number)
(Herrmann et al., 1998).
Subjects were excluded for the following reasons: (1) normal do-
pamine transporter scan based on the Movement Disorder Society
Clinical Diagnostic Criteria for PD (Postuma et al., 2015); (2) with
dementia according to the clinical diagnostic criteria of the Movement
Disorder Society (Emre et al., 2007); (3) neurological abnormalities
related to atypical or secondary parkinsonism; (4) structural or space-
occupying lesions on the basal ganglia; and (5) those who were taking
medications at the time of diagnosis known to influence central dopa-
minergic, noradrenergic, and/or serotonergic systems.
2.2. Imaging acquisition and processing
Brain computed tomography (CT) and 18F-FP-CIT PET images were
acquired using a Discovery STE PET/CT scanner (GE Healthcare,
Milwaukee, WI, USA). After 3 h of intravenous injection of an average
of 3.7MBq/kg of 18F-FP-CIT, brain CT scans were obtained for at-
tenuation correction followed by a 10min 18F-FP-CIT PET scan. PET
images were reconstructed with a 512×512×110 matrix using an
ordered-subsets expectation maximization algorithm. The voxel size
was 0.668×0.668×2mm. Axial T1-weighted brain magnetic re-
sonance images with 3D-spoiled gradient-recalled sequences
(512×512 matrix, voxel spacing 0.469×0.469× 1mm) were also
acquired with a 3.0-T scanner (Magnetom Verio, Siemens, Erlangen,
Germany).
Statistical Parametric Mapping 8 software (SPM8; Wellcome Trust
Centre for Neuroimaging, London, UK) implemented in MATLAB 2015a
(MathWorks, Natick, MA) were utilized for co-registration and spatial
normalization of the images and voxel-based comparisons (Kim et al.,
2015; Oh et al., 2018). Briefly, 18F-FP-CIT PET were co-registered to
individual MR images and spatially normalized to the Montreal Neu-
rological Institute space with parameter-normalizing skull-stripped MR
images. Subject-specific striatal volume of interest (VOI) templates
derived from FreeSurfer 5.1 (Massachusetts General Hospital, Harvard
Medical School; http://surfer.nmr.mgh.harvard.edu), which is regarded
as the gold standard for comparing striatal 18F-FP-CIT PET binding
values, were used. T1-weighted MR images were resliced to 1mm iso-
voxel space, corrected for inhomogeneity, skull-stripped, and seg-
mented into gray and white matter. To measure the striatal subregional
and cerebellar binding values in spatially-normalized PET images, we
created VOI templates for the caudate, putamen, and cerebellum. Then,
the striatal and cerebellar segments were spatially normalized to the
skull-stripped MR template within 1mm-sized isovoxel space. Using the
VOI template, we measured the regional standardized uptake value
(SUV) of the cerebellum and each side of the caudate, putamen, globus
pallidus, thalamus, and ventral striatum in the PET images. We also
used an in-house MATLAB program for simple arithmetic operations on
images and measuring the regional uptake values. Mean SUV ratios
(SUVRs) were calculated as the target SUV divided by the cerebellum
SUV.
2.3. Statistical analysis
All statistical analyses were executed with the Statistical Package
for the Social Sciences, version 24.0 for Mac (IBM Corporation,
Armonk, NY, USA). Pearson's χ2 tests were used to compare frequencies
for categorical variables, and one-way analysis of variance (ANOVA)
tests were used to compare mean differences among the groups. Group
differences of the regional SUVR values were analyzed by analysis of
covariance (ANCOVA), adjusted for age, disease duration and UPDRS
part III score. In a sub-analysis of the striatum, within-group gradient
vector differences by subtracting the SUVR value of posterior putamen
(a preset reference in PD) from the SUVR values of caudate nuclei,
anterior caudate nuclei, posterior caudate nuclei, anterior putamen,
ventral putamen and ventral striatum, were analyzed by paired t-test.
Those gradient values were examined for trend between groups using
the Jonckheere-Terpstra method. A family-wise type I error was set at a
two-tailed p value< .05, and the Bonferroni correction was applied in
cases of multiple comparisons.
3. Results
The clinical characteristics of the studied participants are summar-
ized in Table 1. The mean age (± SD) was 68.6 ± 9.1 years, and 62
subjects (50.4%) were male. The mean disease duration was
1.1 ± 1.6 years, and the modified H&Y stage score was 1.5 ± 0.5. The
mean MMSE score was 27.0 ± 2.7, and there were not any between-
group differences. Of 123 early PD patients, 68 (55.3%) were found to
have depressive moods, and the mean MADRS score was 9.0 ± 7.6.
Subjects in the PD-no depression group were younger than the other
two groups with depression. Indices of disease severity measured by the
UPDRS part III and modified H&Y stage scores showed that subjects
without depression had a milder PD severity than PD subjects with
depression. The frequencies of rest tremor and tremor scores were not
different among the groups.
Between-group analyses of regional SUVR values showed significant
differences in the anterior caudate nucleus and ventral striatum as de-
pression became worse (Table 2 and Fig. 1). The moderate-to-severe
depression group achieved lower SUVR values in both the caudate
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Table 1
Participant clinical characteristics.
All (n=123) Group 1a (n=55) Group 2b (n=54) Group 3c (n=14) p value Post-hoc testd
Age, years 68.6 ± 9.1 65.6 ± 9.2 71.0 ± 8.7 71.4 ± 6.9 0.003 a < b⁎⁎
Sex, Male, n (%) 62 (50.4%) 30 (54.5%) 26 (48.1%) 6 (42.9%) 0.668 a=b= c
Disease duration, years 1.1 ± 1.6 1.1 ± 1.3 1.2 ± 1.9 1.2 ± 1.5 0.900 a=b= c
Body mass index, kg/m2 23.8 ± 3.3 24.0 ± 3.2 24.0 ± 3.6 22.5 ± 2.1 0.290 a=b= c
Education, years 11.2 ± 4.7 12.2 ± 4.7 10.7 ± 4.8 9.4 ± 4.2 0.081 a=b= c
Hypertension, n (%) 52 (42.3%) 20 (36.4%) 24 (44.4%) 8 (57.1%) 0.340 a=b= c
Diabetes mellitus, n (%) 16 (13.0%) 5 (9.1%) 9 (16.7%) 2 (14.3%) 0.495 a=b= c
Never-smoker, n (%) 88 (71.5%) 39 (70.9%) 38 (70.4%) 11 (78.6%) 0.824 a=b= c
MMSE 27.0 ± 2.7 27.6 ± 2.4 26.5 ± 2.5 26.7 ± 3.9 0.128 a=b= c
UPDRS, total score 22.6 ± 10.8 18.1 ± 10.1 25.7 ± 10.3 28.0 ± 9.0 < 0.001 a < b⁎⁎, a < c⁎⁎
Part I 1.6 ± 1.6 0.9 ± 1.0 2.2 ± 1.8 2.2 ± 1.4 < 0.001 a < b⁎⁎, a < c⁎⁎
Part II 6.4 ± 4.0 4.7 ± 3.1 7.6 ± 3.8 8.6 ± 4.9 < 0.001 a < b⁎⁎, a < c⁎⁎
Part III 14.6 ± 7.5 12.5 ± 7.7 16.0 ± 7.3 17.6 ± 5.4 0.014 a < b⁎
Rest tremor, n (%) 73 (59.3%) 32 (58.2%) 34 (63.0%) 7 (50.0%) 0.660 a=b= c
Tremor score 4.0 ± 3.1 4.0 ± 3.0 3.9 ± 3.0 4.4 ± 3.6 0.888 a=b= c
Akinetic rigid score 8.1 ± 4.7 6.7 ± 4.7 9.1 ± 4.6 10.3 ± 4.1 0.006 a < b=c⁎
Modified H&Y stage 1.5 ± 0.5 1.3 ± 0.5 1.6 ± 0.4 1.8 ± 0.4 < 0.001 a < b⁎⁎, a < c⁎⁎
MADRS 9.0 ± 7.6 2.1 ± 1.9 12.4 ± 3.6 23.0 ± 3.3 < 0.001 a < b < c⁎⁎
All patients were stratified into three groups by the Montgomery–Asberg Depression Rating Scale (MADRS). Group 1a, 0–6, no depression; Group 2b, 7–19, mild
depression; and Group 3c, scores of ≥20, moderate-to-severe depression; d Multiple comparisons were adjusted by the Bonferroni method.
Abbreviations: MMSE, Mini-Mental State Examination; UPDRS, Unified Parkinson's Disease Rating Scale; H&Y, Hoehn and Yahr, MADRS, Montgomery–Asberg
Depression Rating Scale (MADRS).
Data is shown as mean ± standard deviation for continuous variables and number with percentage in parenthesis for categorical variable.
One-way analysis of variance was performed for continuous variables and χ2 test for categorical variables to compare between-group differences.
⁎ p < .05.
⁎⁎ p < .01.
Table 2
Regional standardized uptake ratio (SUVR) differences between groups.
Group 1a (n= 55) Group 2b (n=54) Group 3c (n= 14) p value Post-hoc test
Caudate 4.2 ± 1.4 3.6 ± 1.3 2.7 ± 0.9 0.012 a > c⁎, b > c⁎
Right 4.2 ± 1.3 3.8 ± 1.4 2.7 ± 0.9 0.008 a > c⁎, b > c⁎⁎
Left 4.1 ± 1.5 3.5 ± 1.3 2.6 ± 1.1 0.030 a > c⁎
Anterior caudate 4.5 ± 1.5 3.8 ± 1.5 2.7 ± 1.1 0.010 a > c⁎, b > c⁎
Right 4.5 ± 1.5 4.0 ± 1.5 2.7 ± 1.0 0.007 a > c⁎, b > c⁎⁎
Left 4.5 ± 1.7 3.7 ± 1.5 2.7 ± 1.3 0.029 a > c⁎
Posterior caudate 3.4 ± 1.2 3.0 ± 1.1 2.3 ± 0.8 0.054 a=b= c
Right 3.7 ± 1.3 3.3 ± 1.2 2.4 ± 0.9 0.030 a > c⁎, b > c⁎
Left 3.2 ± 1.2 2.7 ± 1.1 2.1 ± 0.8 0.126 a=b= c
Putamen 4.2 ± 1.1 4.1 ± 1.3 3.3 ± 1.0 0.069 a=b= c
Right 4.1 ± 1.4 4.2 ± 1.4 3.2 ± 1.0 0.067 a=b= c
Left 4.2 ± 1.2 4.0 ± 1.4 3.3 ± 1.2 0.136 a=b= c
Anterior putamen 4.3 ± 1.3 4.2 ± 1.5 3.2 ± 1.2 0.046 a=b= c
Right 4.3 ± 1.5 4.4 ± 1.6 3.2 ± 1.1 0.046 a=b= c
Left 4.4 ± 1.4 4.1 ± 1.6 3.2 ± 1.5 0.115 a=b= c
Posterior putamen 3.2 ± 1.2 3.3 ± 1.5 2.7 ± 1.0 0.381 a=b= c
Right 3.3 ± 1.6 3.5 ± 1.7 2.8 ± 1.1 0.350 a=b= c
Left 3.2 ± 1.2 3.1 ± 1.5 2.7 ± 1.1 0.536 a=b= c
Ventral putamen 4.0 ± 1.0 3.8 ± 0.9 3.4 ± 0.7 0.245 a=b= c
Right 4.0 ± 1.1 3.9 ± 1.1 3.3 ± 0.6 0.119 a=b= c
Left 4.0 ± 0.9 3.8 ± 0.9 3.6 ± 0.8 0.442 a=b= c
Globus pallidus 3.4 ± 1.0 3.5 ± 0.9 3.5 ± 1.2 0.935 a=b= c
Right 3.4 ± 1.0 3.5 ± 0.9 3.6 ± 1.4 0.926 a=b= c
Left 3.4 ± 1.1 3.4 ± 0.9 3.3 ± 1.1 0.757 a=b= c
Thalamus 1.5 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 0.150 a=b= c
Right 1.5 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 0.173 a=b= c
Left 1.4 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 0.167 a=b= c
Ventral striatum 5.0 ± 1.1 4.9 ± 1.2 3.8 ± 1.0 0.008 a > c⁎, b > c⁎
Right 4.7 ± 1.2 4.7 ± 1.2 3.5 ± 1.0 0.010 a > c⁎, b > c⁎⁎
Left 5.4 ± 1.2 5.0 ± 1.3 4.0 ± 1.0 0.012 a > c⁎, b > c⁎
All patients were stratified into three groups by the Montgomery–Asberg Depression Rating Scale (MADRS). Group 1a, 0–6, no depression; Group 2b, 7–19, mild
depression; and Group 3c, scores of ≥20, moderate-to-severe depression.
Data is shown as mean ± standard deviation.
Analyses were performed by one-way analysis of variance (ANCOVA) test with Bonferroni post-hoc tests controlling for age, disease duration, and Unified Parkinson's
Disease Rating Scale part III scores.
⁎ p < .05.
⁎⁎ p < .01.
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nuclei and ventral striatum than the PD-no depression group. When the
mild depression group and the moderate-to-severe depression group
were compared, the latter group also had lower SUVR values in the both
anterior caudate, the right posterior caudate, and both ventral striatum.
However, no significant differences were observed upon comparison of
the SUVR values between the no depression group and the mild de-
pression group.
Table 3 summarizes the within-group differences of SUVR values
between the antero- and ventral regions of the striatum with a reference
posterior putamen area. Antero- and ventroposterior gradient of SUVR
value was found within each group. Interestingly, the anteroposterior
gradient between the anterior caudate nucleus and posterior putamen
disappeared as the severity of depression increased (Group 1, p < .001;
Group 2, p= .029; Group 3, p= .934). A strong significance of ven-
troposterior gradient remained across the groups. Inverse dose-depen-
dent associations were found between within-group sub-region differ-
ences as depression worsened (Fig. 2).
4. Discussion
The participants of this study exhibited distinctive regional dopa-
mine transporter uptake patterns depending on the degree of depression
in early PD. In a subgroup analysis of the striatum, an antero- and
ventroposterior gradient of SUVR values was found when the posterior
putamen was defined as a reference area. The gradient also manifested
an inverse dose-dependent relationship with worsening depression.
In previous studies, the caudate (Koerts et al., 2007; Vriend et al.,
2014) and ventral striatum (Remy et al., 2005) with dopaminergic
deficits were related to depression in PD. Similar results were observed
in this study, but with more details which were compatible with the
established neurocircuitry of mood. Caudate nuclei, especially the
anterior part and ventral striatum, are key substructures within dis-
tinctive basal ganglia circuits that are associated with affect and psy-
chomotor fatigue (Price and Drevets, 2010; Stahl, 2013; Tremblay
et al., 2015). The findings of this study substantiate this in vivo.
The caudate (with more anterior part) and the ventral striatum were
inversely associated with MADRS total score, signifying that the se-
verity of depression is related to the amount of disrupted mono-
aminergic systems in subregions relevant to mood (Frisina et al., 2009;
Hesse et al., 2009; Price and Drevets, 2010; Remy et al., 2005). How-
ever, the dopamine transporter uptakes were not different between the
no depression group and the mild depression group in this study. The
MADRS scores of the mild depressive group were 12.4 ± 3.6, meeting
the subthreshold for clinically relevant depression (Schrag et al., 2007).
The SUVR value change reached a critical point in the moderate-to-
severe group, surpassing the symptomatic threshold. Substructural
changes that correspond to depression may occur after a greater loss of
nigro-putamen projection in an independent process; different thresh-
olds for each of the limbic, associative and sensorimotor functional
parallels seem to exist (Brooks and Piccini, 2006; Price and Drevets,
2010; Tremblay et al., 2015). This argument explains for such disparity
in the between-group differences.
In this study, we analyzed gradient patterns within basal ganglia, an
approach which had been used before with a different methodology
Fig. 1. Voxel-based comparison of 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane positron emission tomography (18F-FP-CIT PET)
controlling for age, disease duration, and Unified Parkinson's Disease Rating Scale part III scores. (A) no depression vs. moderate-to-severe depression, (B) mild
depression vs. moderate-to-severe depression. The differences of the standardized uptake value ratios (SUVRs) between groups were demonstrated in the colored
region. T values are indicated by the color bar.
Table 3
Within-group standardized uptake ratio (SUVR) gradients by subtracting the SUVR value of the posterior putamen from each anterior subregion.
Sub-region Group 1 (n= 55) p value Group 2 (n= 54) p value Group 3 (n= 14)) p value
Caudate 0.9 ± 1.6 < 0.001 0.4 ± 1.7 0.120 −0.1 ± 1.4 0.830
Anterior caudate 1.2 ± 1.7 < 0.001 0.6 ± 1.8 0.029 −0.03 ± 1.5 0.934
Posterior caudate 0.2 ± 1.5 0.462 −0.3 ± 1.6 0.131 −0.5 ± 1.4 0.214
Anterior putamen 1.1 ± 0.6 < 0.001 0.9 ± 0.8 < 0.001 0.5 ± 0.5 0.004
Ventral putamen 0.7 ± 0.7 < 0.001 0.5 ± 1.0 < 0.001 0.7 ± 0.8 0.005
Ventral striatum 1.8 ± 0.9 < 0.001 1.6 ± 1.2 < 0.001 1.0 ± 0.9 0.001
All patients were stratified into three groups by the Montgomery–Asberg Depression Rating Scale (MADRS). Group 1, 0–6, no depression; Group 2, 7–19, mild
depression; and Group 3, scores of ≥20, moderate-to-severe depression.
Data is shown as mean ± standard deviation.
Analysis was performed paired t-test to find within-group differences between areas of interest and posterior putamen.
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(Oh et al., 2012). This study's method is plausible if we consider the
gradient as a vector with a fixed point. Vector is a term that includes
magnitude and direction. Simple subtraction between SUVR values of
substructures does not cancel out the ratio of the cerebellum, thus
rendering it suitable for analysis. In a subanalysis of the striatum, for-
ward and ventral gradients of SUVR values with posterior putamen
possessing the lowest reference values were observed. In PD, the pos-
terior putamen, where the sensorimotor loop is located, becomes pre-
dominantly and preferentially affected in 18FP-CIT PET images (Brooks
and Piccini, 2006; Tremblay et al., 2015). Its lower dopamine trans-
porter uptake reflects the selective neuropathological process in PD
(Braak et al., 2003). With disease progression, the posterior putamen
dopamine transporter uptake falls further while the ventral and anterior
putamen and the dorsal caudate integrity become involved (Brooks and
Piccini, 2006). The ventral striatum remains spared until the late stage
(Brooks and Piccini, 2006; Oh et al., 2012; Tremblay et al., 2015).
Within each group, the posterior putamen displayed the lowest uptake,
forming antero- and ventroposterior gradients between substructures.
This trend was found across the subgroups with increasing severity of
depression, except that the caudate-putamen gradient lost its sig-
nificance. This corresponds with the accepted predominant role of the
ventral striatum in the limbic system, whereas the caudate is more
associated with cognition despite its participation in depression
(Tremblay et al., 2015; Vriend et al., 2014). Subregional gradients
within a group and negative dose-dependent associations across groups
in early PD can be explained by its independent process and lower
threshold than sensorimotor territory. This analysis might suggest in
vivo causal relationship between dopaminergic modulation of the ven-
tral striatum and depression in early PD.
18F-FP-CIT is a radioligand that has differential monoaminergic
binding affinity relevant to anatomical structures. It is known to
strongly reflect dopamine transporter in the striatum whereas it almost
exclusively represents serotonergic transporter in thalamus (Hesse
et al., 2009; Koch et al., 2014). This further enhances the argument of
this study that disrupted dopaminergic modulation of the striatum is
relevant to the depression severity.
This study has a few advantages compared to other studies. First,
this study utilized the MADRS which has been validated in PD. It is
accepted as suitable because it has relatively few somatic items (Schrag
et al., 2007). The Beck Depression Inventory (BDI) is also validated in
PD, but it contains several somatic symptoms (Schrag et al., 2007). A
study using BDI as an assessment tool showed that mood was unrelated
to striatal dopaminergic deficits (Broussolle et al., 1999), but such a
result might have been confounded by the somatic effects of the scale.
Second, we utilized a methodology that allowed spatial normalization
of the PET images to quantify presynaptic monoamine transporter
densities in a relatively large number of subjects. PET is a more ad-
vantageous method of quantitative instrumentation than single photon
emission computed tomography (SPECT) (Oh et al., 2012; Rektorova
et al., 2008). Visual and semi-quantitative analyses can be biased due to
image noise and sampling errors. The MR-guided spatial-normalization
method is considered more accurate and works independently from
receptor density (Ashburner and Friston, 1999; Gispert et al., 2003; Kim
et al., 2015).
Fig. 2. Dose-dependent relationships of antero- and ventroposterior gradient of standardized uptake value ratio (SUVR) values with increasing depression severity.
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However, our study has limitations, including its cross-sectional
design. First, depression was investigated at the time of PD diagnosis.
The MADRS assessment at diagnosis can be associated with the five
stages for illness, death, and transition (Kübler-Ross, 1969), affecting
the depression assessment scale. In addition, motor disability is known
to affect depression in PD (Aarsland et al., 2011). In this study, we only
enrolled patients at an early disease stage with short disease duration.
Such selection of study subjects can abate the confounding influence of
motor disability. Furthermore, motor disability was statistically ad-
justed to minimize its influence on the association between striatal 18F-
FP-CIT uptake and depression. A long-term cohort that studies the in-
fluence, treatment response, and interaction of depression with motor
and other non-motor burdens could clarify such clinical implications.
Second, the number of subjects in the moderate-to-severe depressive
group was relatively small compared to the other groups. In early PD
patients, non-medicated moderate-to-severe depressive patients were
extremely rare; most patients with severe depression were on anti-
depressants. Third, because 18FP-CIT ligand has preferential binding
affinity to different monoamine transporters according to its anatomical
substrates, possible contributions of other neurotransmitters associated
with noradrenergic and serotonergic systems to depression in PD
cannot be neglected. Lastly, the results would be more empiric if the
study included comprehensive cognitive examinations. Cognitive
symptoms in PD could influence the results of MADRS as “concentration
difficulties,” and “lassitude” subscales may be related to cognition in
relevance to striatal dopaminergic deficits (Koerts et al., 2007). Mild
cognitive impairment is also known to occur in the early stage of PD
(Litvan et al., 2012). and its relation to mood, including depression and
apathy, would enhance the clinical implications (Rektorova et al.,
2008).
In conclusion, depression in early PD is related to dopaminergic
modulation in the caudate, especially the anterior part, and the ventral
striatum. This study might contribute to unveiling the causal relation-
ship between mood and basal ganglia functional sub-territories in vivo.
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